In the global pharmaceutical and health industry, the regulatory policies formulated by various countries for drugs and health products are like an invisible but powerful hand, which profoundly affects the development direction of the capsule industry. From the strict control of production standards to the setting of market access thresholds, regulations and policies play a key role in every link.
United States: St
rict standards and dynamic adjustments
As the world's largest pharmaceutical market, the regulations and policies formulated by the Food and Drug Administration (FDA) of the United States have a far-reaching impact on the capsule industry. In the production process, the FDA has extremely strict requirements on the source and quality standards of capsule raw materials. For example, for animal-derived gelatin commonly used in gelatin capsules, from disease prevention and control in the animal breeding process to the hygiene standards of gelatin extraction process, strict regulations must be followed to prevent potential risks such as mad cow disease from entering the pharmaceutical system through capsules. In terms of plant-derived capsules, such as hydroxypropyl methylcellulose hollow capsules, although they have advantages such as a wide source of raw materials and good safety, the FDA's approval process is still cautious. At present, there are about 21 registration numbers for cellulose and hydroxypropyl methylcellulose hollow capsules registered and activated by the US FDA, 2 registration numbers for hydroxypropyl starch hollow capsules, and only 1 registration number for pullulan hollow capsules, which has not yet been activated, which reflects its high standards and strict requirements for the approval of new products.
In addition, the FDA's policies are also dynamically adjustable. With the development of medical technology and the deepening of the understanding of drug safety, policies are constantly updated and improved. For example, in terms of drug quality consistency evaluation, higher quality index requirements such as dissolution are proposed for drugs in capsule dosage form, which prompts capsule manufacturers to continuously improve production processes and improve product quality stability to meet the needs of drug manufacturers for high-quality capsules, otherwise they will face the risk of their products not being able to enter the US market.
Europe: Coordination and supervision under a multi-system
The drug regulatory systems of European countries are diversified, and at the same time, they are coordinated and unified within the region through the European Medicines Agency (EMA). In the capsule industry, authoritative pharmacopoeias such as the European Pharmacopoeia (EP)/British Pharmacopoeia (BP) have detailed provisions on capsule quality standards, covering physical properties, chemical stability, microbial limits and other indicators. For example, in terms of disintegration time, strict time ranges are set for different types of capsules to ensure that the drug can be released as expected in the human digestive system.
In terms of market access, EU countries require capsule manufacturers to obtain relevant quality certifications, such as ISO quality management system certification and Good Manufacturing Practice (GMP) certification. These certifications not only involve standardized management of the production process, but also include considerations of the company's R&D capabilities and personnel qualifications. For capsule products imported from outside the EU, they also need to meet various EU regulations and standards, which undoubtedly increases the difficulty for non-EU capsule companies to enter the European market. However, this strict regulatory environment has also prompted European local capsule companies to continue to innovate and develop more distinctive and advantageous products, such as capsules with special sustained-release functions, to meet the increasingly diverse needs of pharmaceutical preparations.
China: Continuous Improvement and Industry Promotion
In recent years, China's regulatory policies on drugs and health products have continued to improve. In the capsule industry, the National Medical Products Administration (NMPA) has continuously optimized the review and approval process on the basis of ensuring the safety, effectiveness and quality control of drugs. The "Announcement of the National Medical Products Administration on Further Improving the Related Review, Approval and Supervision of Drugs" issued in 2019 changed the separate approval of pharmaceutical excipients (including capsules) to a review and approval when approving drug registration applications, which improved the approval efficiency. At the same time, although the cognition is limited, new products such as plant-derived capsules are also being actively explored. For example, when faced with the problem that the disintegration time of hydroxypropyl starch hollow capsules is longer than that of gelatin hollow capsules, which may affect the quality and effectiveness of drugs, NMPA organized relevant departments to jointly participate in the formulation of starch capsule dissolution test standards and revised the relevant guidelines for the current dissolution comparison study to promote the healthy and orderly development of the pharmaceutical excipients industry.
In terms of production supervision, China implements a strict GMP certification system for capsule manufacturers, regulating the entire process from plant facilities, equipment management, personnel operation to material procurement. In addition, with the enhancement of environmental awareness, the environmental protection requirements in the capsule production process are also increasing, prompting companies to adopt more environmentally friendly production processes and raw materials, which to a certain extent promotes the development of environmentally friendly products such as plant-derived capsules.
Other regions: distinctive regulatory strategies
In other countries in the Americas, in September 2022, the 30th Pan American Health Conference of the Pan American Health Organization (PAHO) adopted a policy to strengthen the national regulatory system for drugs and other health technologies, aiming to ensure that drugs and health technologies are safe, effective, high-quality, and meet the needs of national health systems. The implementation of this policy will prompt countries in the Americas to strengthen the supervision of drug-related products such as capsules, standardize them from quality control to market circulation, and promote the local capsule industry to develop in a more standardized and standardized direction.
In other countries and regions in Asia, such as Japan, its Pharmaceuticals and Medical Devices Administration (PMDA) has strict approval and regulatory processes for drug excipients including capsules, focusing on product safety and quality stability. Japanese companies have been relatively active in the research and development of capsule technology. While encouraging innovation, regulations and policies also ensure the high-quality supply of capsule products on the market.
The regulatory policies of various countries on drugs and health products shape the development pattern of the capsule industry in many ways. Strict standards prompt companies to improve product quality and innovation capabilities, while dynamic policy adjustments require companies to remain sensitive and adapt to changes in a timely manner. For the capsule industry, continuously optimizing its own production and operations under the guidance of laws and policies will be the key to gaining an advantage in global market competition.